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Binding site characterizationBased on the attrition rate of CCR5 small molecule antagonists in the clinic the discovery and development of
next generation antagonists with an improved pharmacology and safety proﬁle is necessary. Herein, we
describe a combined molecular modeling, CCR5-mediated cell fusion, and receptor site-directed mutagenesis
approach to study the molecular interactions of six structurally diverse compounds (aplaviroc, maraviroc,
vicriviroc, TAK-779, SCH-C and a benzyloxycarbonyl-aminopiperidin-1-yl-butane derivative) with CCR5, a
coreceptor for CCR5-tropic HIV-1 strains. This is the ﬁrst study using an antifusogenic assay, a model of the
interaction of the gp120 envelope protein with CCR5. This assay avoids the use of radioactivity and HIV
infection assays, and can be used in a high throughput mode. The assay was validated by comparison with
other established CCR5 assays. Given the hydrophobic nature of the binding pocket several binding models
are suggested which could prove useful in the rational drug design of new lead compounds.erlj).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.The successful treatment of Acquired Immune Deﬁciency Syn-
drome (AIDS) has been due to the introduction of Highly Active
Antiretroviral therapy (HAART). Two classes of HIV drugs (e.g.
proteases and reverse transcriptases) are used in HAART to delay or
stop the progression of AIDS. However, because of side effects,
development of resistance, and challenges with patient compliance
there is a continuing demand for new generations of viral inhibitors.
Ideally, other classes of drugs interfering with viral replication by new
mechanisms could complement existing therapies (Barber, 2004;
Lusso, 2006; Markovic, 2006; Nadler and Phillips, 2005).
One such new class, the entry inhibitors, prevents HIV entry into
the target cell. In order for HIV to infect the host cell the gp120 viral
envelope protein must ﬁrst bind to the CD4 receptor, and then to
either one of two chemokine coreceptors, CCR5 or CXCR4, which are
G-protein coupled receptors, members of the seven-transmembrane
domain family. Antagonists inhibiting or altering the interaction of
HIV with these two coreceptors prevent viral fusion with the cellmembrane, which ultimately results in viral load reduction when
administered to humans (Allen et al., 2007). While CCR5 is used as a
coreceptor in the early stages of infection, the CXCR4 coreceptor using
virus is linked to signiﬁcant disease progression leading to AIDS. In
contrast to in vitro results, other chemokine receptors have not been
found to play a role as coreceptors for HIV infection under in vivo
conditions (Dragic, 2001; Kazmierki et al., 2005).
The important role of these chemokine receptors in the HIV
infection process was discovered in 1998, which led to a new
classiﬁcation of the three main HIV variants based on their chemokine
receptor selectivity: these classiﬁcations are CXCR4-tropic (X4),
CCR5-tropic (R5), and dual-tropic (R5/X4) (Berger et al., 1998).
The development of smallmolecule antagonists of CCR5 to blockHIV
entry has been pursued by several pharmaceutical companies and
multiple compounds have been evaluated in the clinic (Faetkenheuer
et al., 2005; Klibanov, 2009; Kromdijk et al., 2010; Lalezari et al., 2005;
Lenz and Rockstroh, 2010; Palani and Tagat, 2006; Perry, 2010; Sayana
and Khanlou, 2009; Shuermann et al., 2007; Strizki et al., 2005; Tilton
et al., 2010;Wilkin et al., 2010). These small molecule antagonists have
been found to bind within a binding pocket formed by the transmem-
brane helices (Billick et al., 2004; Dragic et al., 2000; Castonguay et al.,
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Stupple et al., 2011; Seibert et al., 2006; Tsamis et al., 2003). The fact that
these antagonists are small compared toHIVgp120 and that theybind in
a cavity within the receptor makes it unlikely that a direct competition
could occur between these inhibitors and gp120. Instead, mechanistic
studies have indicated that these antagonists act via an allosteric
mechanism, changing the conformation of the receptor and thus
preventing the interaction of gp120 with CCR5 (Dragic et al., 2000;
Watson et al., 2005). Though the details of this allostericmechanism are
not fully understood, the concept of allosteric inhibition provides the
opportunity to develop structurally diverse CCR5 antagonists with
different binding interactions potentially inducing different conforma-
tional changes of the receptor which are incapable of interacting with
the virus leading to different resistance proﬁles. To date only one CCR5
antagonist has successfully progressed through all the developmental
hurdles. Pﬁzer'smaravirocwas approved by the FDA for use in treatment
experienced patients in August 2007 (Perry, 2010; Sayana and Khanlou,
2009) and following further clinical trials was approved for use in
treatment-naïve patients with CCR5-using virus in November 2009
(Kromdijk et al., 2010).Other agentshavebeen less successful. As theﬁrst
of its class, TAK-779was tested in clinical trials, but failed because of poor
pharmacological and/or toxicological properties as well as lack of oral
bioavailability (Palani and Tagat, 2006). Schering-Plough has progressed
two compounds (SCH-C and vicriviroc) into the clinic. However, Phase I
studies of SCH-C were discontinued because of prolongation of the QT
interval and Phase II studies involving treatment-naïve patients with
vicriviroc were stopped because of the increased likelihood of viral load
rebound compared to a group of patients using standard therapy. In
addition based on results of two Phase III trials of vicriviroc in treatment-
experienced HIV-positive patients, vicriviroc did not meet its primary
efﬁcacy endpoint therefore, Merck will not submit an NDA for vicriviroc
(Merck, 2010). Development of aplaviroc, originally developed by OnoFig. 1. Snake plot representation of CCR5; the mutated residues tested in thPharmaceuticals (Maeda et al., 2004) and licensed by GlaxoSmithKline,
washalted after patients in Phase II and III trials experienced liver toxicity
(Crabb, 2006). Thus, given the high attrition rate of compounds in the
clinic increasing the understanding of how smallmolecules bind to CCR5
should help in developing structurally diverse antagonists with different
pharmacokinetic, pharmacodynamic and resistance proﬁles.
In this paper we provide a comprehensive description of the binding
of the aforementioned antagonists to CCR5 using an antifusogenic assay,
which mimics the interaction of the viral envelope protein with CCR5.
After validating this assay with other in-house data (natural ligand
binding and HIV-1) and by comparing the effect of selected CCR5 amino
acidmutations on smallmolecule inhibition, an in-depthmutant study of
the potential allosteric binding site has been conducted. The conclusions
of this study are based primarily on our fusion assay data, with additional
literature information used to reﬁne our small molecule binding
hypotheses. This work is in line with other mechanistic studies aimed
at a better understanding of small molecule binding and inhibition of
CCR5. Notably, use of the fusion assay provides a physiologically relevant
technique for investigating drug/receptor interactions with themerits of
not requiring active virus, andwithin a short assay time. Furthermore the
binding models provided by this assay, and reported in this paper, can
provide valuable insights for rational drug design.
Results
Validation of a huCCR5/gp120 fusion assay as a technique for
interrogating compound/receptor interactions using receptor
site-directed mutagenesis
The amino acid sequence of CCR5 is shown as snake plot in Fig. 1
together with 34 single-site mutants to encompass all possibilities for
small molecule binding sites (Table 1).e current study are highlighted and important residues are annotated.
Table 1
Replicate analysis of amino acid mutations on fusion inhibition for the inhibitor SCH-C.
Mutation Mean IC50 SEM N
Wild type 4.7 0.92 72
K26A 7.2 0.75 17
A29G 7.8 1.56 6
R31A 4.9 0.65 9
L33A 131.3 8.93 41
Y37A 972.7 68.89 56
Y37F 1.2 0.19 16
F79A 127.8 15.21 25
W86A 6404.8 544.54 38
T105A 79.4 13.33 4
Y108A 65.26822 4.563691 45
Y108F 42.994 11.33901 5
F109A 8.388261 0.75688 47
F112A 10.67273 1.075188 33
F113A 6.25963 0.848724 27
S180A 14.11 3.978145 6
H181A 6.7025 0.966474 4
F182A 48.32 5.729915 5
Y184A 4.2075 0.630653 4
S185A 5.595714 1.203382 7
Q186A 2.71 0.681726 4
Y187A 8.4875 1.90384 4
K191A 41.82545 5.437848 11
T195A 1.805556 0.195634 9
K197A 6.58125 0.787672 8
I198A 349.9956 63.94876 9
Y251A 0.9 0.13 36
Y251F 0.7 0.03 9
N252A 12.4 1.79 8
L255A 17.8 1.89 15
T259A 6.3 2.31 3
Q280A 7.3 1.42 10
T282A 18.8 5.18 5
E283A 9827.3 120.18 32
T284A 3.5 0.29 38
SEM: standard error mean; N: number of measurements.
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brane region and span the whole cross section of the receptor. HeLa-
CD4-LTR-β-gal cells were transiently transfectedwith either wild type
CCR5 or mutant CCR5 (see Materials and methods). None of the
mutants had a signiﬁcant impact on CCR5/gp120 fusion, giving similar
base line fusion to wild type CCR5. This is shown in Fig. 2 for a selected
group of mutants which were found to play a signiﬁcant role in
inhibitor binding (see below). There was inter-assay variation in
base line fusion between experiments conducted on different days
attributed to the variability conferred by transient transfection (data
not shown).
In order to validate the fusion assay the assaywas comparedwith a
125I-RANTES competition binding assay and a HIV assay. The binding
competition experiments investigate the ability of small molecules to
inhibit natural ligand binding. The HIV assay is, like the fusion assay, a
functional assay and is the relevant therapeutic endpoint. The fol-
lowing CCR5 mutants were chosen primarily based upon their role inFig. 2. Selected dose/response curves for the fusion assay for the inhibitor SCH-C.inhibitor binding as reported in the literature: E283A, W86A, Y37A,
Y108A, I198M and L33A which were shown to have a signiﬁcant
contribution to inhibitor binding, and A29G and Y251F which had a
minor contribution (Billick et al., 2004; Dragic et al., 2000; Castonguay
et al., 2003; Kondru et al., 2008; Maeda et al., 2006; Nishikawa et al.,
2005; Seibert et al., 2006; Stupple et al., 2011; Tsamis et al., 2003). The
effects of these mutations on receptor/compound interaction on the
small molecule antagonists shown in Fig. 3 were compared using the
three assays (Fig. 4).
Qualitatively the same trend is observed in all three assays. For
instance, the dynamic range of the assays asmeasured by fold increase
of the IC50 for inhibition increases for most compounds in the order
RANTES binding≤Fusion≤HIV. As an example the L33A substitution
for SCH-C, lowered the RANTES binding inhibition by 20-fold, fusion
inhibition by 500-fold and HIV inhibition by 1000-fold. However for
TAK-779, upper detection limits of each assay restricted the
maximum obtainable fold change. For example, the maximum
measurable fold change for HIV inhibition of TAK-779 for the L33A,
Y37A, W86A and Y108A mutations was 100-fold while a 1000-fold
change was obtainable in the fusion assay.
Despite the observed fold differences as well as variable assay
sensitivities due to the inherent nature of the assays, this comparison
validated the reliability of the fusion assay by consistently identifying
key residues generally considered as important for small molecule
binding to CCR5. Therefore, the fusion assay was used to investigate
the binding modes of CCR5 antagonists in more detail.Effects of small molecule CCR5 antagonists on gp120 interaction with
CCR5 mutants
For the fusion assay a wide range of mutants encompassing the
N-terminus, the transmembrane region and the extracellular loop 2
were tested (Tables 1 and 2 and Fig. 1).
The inhibition of both wild type and mutant CCR5 by the test
inhibitors was reproducible between experiments conducted on dif-
ferent days. The reproducibility of the fusion assay for SCH-C is shown
in Table 1. Typical dose/response curves for the fusion assay for SCH-C
are shown in Fig. 2. Mutation studies supported by information from a
homology model of CCR5 were performed to investigate the binding
site for each compound. This data was used to propose bindingmodels
for the small molecule antagonists with CCR5.The extracellular region
Mutations of residues in the extracellular region have only a minor
impact on the viral inhibition of compounds in the fusion assay.
Despite the low fold changes caused by these mutations in the extra-
cellular region, the two residues Lys26 and Lys191 (Table 2) could
potentially function as interaction sites. This is suggested by ad-
ditional experimental data from the literature (Maeda et al., 2006).The transmembrane domain
The mutation studies reveal that all compounds depend on
residues sharing a common potential binding site in the transmem-
brane region deﬁned by helices TM1, TM2, TM3, TM5, TM6, and TM7,
and beneath ECL2 (Fig. 1). The homologymodel of CCR5 indicates that
this binding site (Fig. 5) can be approximately described by a
negatively charged center (Glu283) surrounded by charge compen-
sating potentially hydrogen-donating residues (Thr105, Tyr108, Tyr251
and Thr284). Two hydrophobic aromatic pockets located in the TM1
and TM2 (Leu33, Tyr37, Phe79 and Trp86) and in the TM3, TM5 and TM6
region (Thr105, Tyr108, Phe109, Ile198 and Tyr251) ﬂank this polar center.
Though all investigated compounds appear to share a common
binding site, analysis of the mutant data in more detail reveals
different dependencies on individual residues.
Fig. 3. Molecular structure of SCH-C, vicriviroc, TAK-779, aplaviroc, 3bb and maraviroc.
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Starting from the center of the binding site (Fig. 5) the mutation of
Glu283 to alanine strongly decreased the inhibitory effects of all small
molecules with the exception of TAK-779 (Table 2). It is proposed that
the negatively charged carboxylate of Glu283 can interact with the
positively charged nitrogen of the small molecule inhibitors. The lack
of dependency of TAK-779 on this interaction could be explained by
steric hindrance around the quaternary nitrogen of TAK-779.
The alanine and phenylalanine mutations of Tyr108 divided the
investigated compounds into two groups. The Y108F and Y108A
mutations had similar effects for vicriviroc, aplaviroc and TAK-779
suggesting the importance of the OH group. The Y108A mutant had a
larger effect on the inhibition of fusion by SCH-C, maraviroc and 3bb
indicating the signiﬁcance of the aromatic part of the side chain.
The comparable IC50 fold increase upon alanine and phenyl
substitution of Tyr251 for maraviroc demonstrated the importance of
the OH function on Tyr251. While the Y251F mutant remains sensitive
to inhibition by 3bb, the Y251A mutant lowered the fusion inhibition
by 64-fold. This emphasizes the aromatic character of the side chain of
Y251 for the 3bb/CCR5 interaction. For the other compounds these
two mutations had a less pronounced impact.
The replacement of Thr284 with alanine only affected the binding
of TAK-779 and 3bb, while the T105A mutation affected only SCH-C
and 3bb.
The hydrophobic binding pocket in TM1 and TM2
The interaction of SCH-C and vicriviroc to CCR5 was only affected
by the Y37A mutation but not by the Y37F mutation highlighting the
signiﬁcance of the aromatic moiety of Tyr37. The inhibitory activity of
TAK-779 was affected by the Y37A and to some extent by the Y37F
mutation indicating that the OH function could play a role in ligand
binding. Maraviroc, 3bb, and aplaviroc were all dependent on Tyr37.
While the W86A mutation had an impact on all compounds, the
L33A mutation reduced the fusion of SCH-C, vicriviroc and TAK-779
but had no effect on maraviroc, 3bb and aplaviroc.The Phe79 residue is located deeper inside the transmembrane
region and therefore could have an indirect effect on small ligand
binding. While the F79A mutation only slightly impacted the
interaction of TAK-779, the loss of the aromatic group had a more
signiﬁcant impact on the interaction of the two Schering compounds
and aplaviroc with CCR5. None of the other compounds were
signiﬁcantly affected by the F79A mutation.
The hydrophobic binding pocket in TM3, TM5 and TM6
The F109A mutation had the largest impact on aplaviroc inhibition
of CCR5-mediated fusion, followed by vicriviroc. Surprisingly, the
structurally related SCH-C did not depend on F109A. The other
compounds showed only minor dependency on this mutation.
The substitution of alanine for Ile198 affected fusion inhibition in
the order maravirocNaplavirocNvicrivirocNSCH-CN3bb. TAK-779
was the only compound unaffected by the I198A mutation. The
substitution of Ala for Thr105 in TM3 attenuated the inhibition of
fusion by SCH-C and 3bb while the other compounds remained
unaffected.
Other residues exerted only minor effects on fusion inhibition
upon alanine substitution.
Interactions of small molecule CCR5 antagonists with huCCR5 based on
molecular modeling
The compounds were docked into the binding site with an ionic
interaction between Glu283 and a positively charged N-atom. This
seemed reasonable given that this interaction has by far the largest
impact on inhibition of most compounds in several assays. The
resulting binding mode should explain as many mutant results as
possible by direct ligand–receptor interactions. Some of the experi-
mentally observed mutant fold increases were less clearly interpret-
able because they not only represent potentially weaker interactions
as demonstrated by the low IC50 fold changes but also because of the
non-directional character typical for hydrophobic interactions.
Fig. 4. Fold changes of substitutions of CCR5 residues in the presence of A) SCH-C; B) vicriviroc; C) 3bb; D) TAK-779; E) aplaviroc: inhibition of 125I-RANTES is incomplete (Watson
et al., 2005) and therefore not included; F) maraviroc in HIV (circles), fusion (squares) or RANTES binding assay (triangles). The upper detection limit of the HIV assay is indicated
(dashed line). For the two other assays the upper detection limit is not in the indicated range of fold difference of 10,000. The different assays demonstrate a similar dependency on
the selected amino acids used for validation.
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orientations for a small molecule antagonist in the binding site exist
where the interaction between Glu283 and the cationic nitrogen is
maintained.
Two different binding modes for SCH-C were proposed (Fig. 6A
and B) in which the compound extends over nearly the whole binding
site into the two hydrophobic pockets (Tyr37, Trp86, Tyr108 and Ile198
in Fig. 6A and B) and a hydrogen bond is formed between Thr105 and
the carbonyl oxygen of the aromatic amide group (Fig. 6A) or with the
oxime (Fig. 6B). The Phe79 is assumed not to be part of the binding
pocket. For vicriviroc similar binding modes were obtained (Fig. 6C
and D). Several residues in the ECL2 (Table 2), which cover the top of
the binding site, as well as residues in the transmembrane region
were silent (Table 2: Phe112, Tyr251, Asn252, Leu255, and Gln280) despite
their potential to interact with both compounds as detailed in the
Discussion.
Aplaviroc was docked into the CCR5 binding site forming po-
tentially two ionic interactions with residues in the binding pocket.Besides the ionic hydrogen bond interaction between the protonated
nitrogen and E283, a second interaction is possible between the
carboxylic group and K191 in the ECL2 (Fig. 6E) or Lys26 in the
N-terminus (Fig. 6F). The elongated shape of the molecule allows
the simultaneous interaction with Glu283 in the center of the
binding site and charged residues in the periphery, as well as with
residues of the two hydrophobic binding pockets (Fig. 5), especially
with Trp86, Phe109 and Ile198. On the other hand, interactions with
Leu33, Tyr37, Phe112, Tyr251, Asn252 and Leu255 were silent.
For TAK-779 two binding modes were proposed in which the
tetrahydropyran moiety forms a hydrogen bond interaction with
Thr284 and hydrophobic interactions with Tyr37 and Trp86. Despite a
low fold decrease for the E283A mutation (Table 2), an ionic
interaction is proposed between the quaternary nitrogen and
Glu283. Other experimental results (Fig. 4D) conﬁrm this potential
interaction. The remaining part of TAK-779 approaches Tyr108 and
other hydrophobic groups on the right hand side of the binding pocket
(Fig. 6G and H). Because none of the residues in the TM5, and TM6
Table 2
Fold differences of amino acid mutation on fusion inhibition. The following mutations
do not signiﬁcantly change the effect of any compound: A29G, R31A, F112A, S180A,
H181A, F182A, Y184A, S185A, Q186A, Y187A, T195A, K197A, N252A, L255A, T259A,
Q280A and T282A. Wild type fusion IC50s in parentheses for: 3bb (2.2 nM), SCH-C
(4.7 nM), TAK-779 (24 nM), aplaviroc (3.8 nM), vicriviroc (0.86 nM), and maraviroc
(0.84 nM).
Locationa Mutant 3bb SCH-C TAK-
779
Aplaviroc Vicriviroc Maraviroc
N-ter K26A 0.5 1.5 1.3 6.6 2.0 0.5
TM1 L33A 0.3 28 32 1.7 22 0.2
TM1 Y37A 0.7 208 273 0.6 395 1.7
Y37F 0.3 0.3 16 0.4 0.5 2.5
TM2 F79A 9.6 27 8.3 21 192 7.1
TM2 W86A 849 1367 378 477 1205 83
TM3 T105A 49 17 0.4 8.9 2.9 1.1
TM3 Y108A 200 60 146 16 51 207
Y108F 51 9.2 111 22 46 51
TM3 F109A 0.2 1.9 7.0 2620 27 0.6
TM3 F113A 0.3 1.3 0.7 8.8 9.8 0.2
ECL2 K191A 1.9 8.9 3.7 6.3 2.0 3.4
TM5 I198A 26 75 0.6 110 83 256
TM5 Y251A 64 0.3 4.4 0.2 3.3 69
Y251F 0.2 0.2 0.1 1.9 0.4 28
TM7 E283A 4627 2077 5.5 1273 12109 11118
TM7 T284A 26 0.9 39 4.2 0.9 5.7
Fold differences are deﬁned as mutant IC50/wild type IC50.
a N-ter = N-terminus, TM = transmembrane helix; ECL = extracellular loop; see
Fig. 1 for a schematic location.
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the biphenyl moiety is less clearly deﬁned. According to the spatial
restrictions of the binding site the hydrophobic biphenyl moiety was
docked to interact with residues deeper in the transmembrane region
(Fig. 6G) or to reach ECL2 (Fig. 6H). However, residues potentially
functioning as interaction sites in these binding pockets were all silent
(Table 2: Phe109, Phe112, Phe113, Gln186, Tyr187, Ile198, Asn252, Leu255,
and Tyr251).
For 3bb two binding modes were suggested (Fig. 6I and J), which
extend over the whole CCR5 antagonist binding pocket (Trp86, Tyr108,
Ile198 and Tyr251 in Table 2) and utilize Thr284 and Thr105 as hydrogen
bond donating interaction sites. As in the case of the other compounds
several residues, which could act as potential binding sites, were
silent (Table 2: Leu33, Tyr37, Phe113, Lys191, Asn252, Leu255, and Gln280).
Based on available fusion mutant data maraviroc was docked into
the binding site allowing an aromatic interaction of the 1,3,4-triazoleFig. 5. CCR5 binding site shared by small molecule antagonists (extracellular view);moiety with Trp86 and a hydrophobic interaction between the di-
ﬂuoro-cycloalkyl group and Tyr108 and Ile198. A potential hydrogen
bond interaction between Tyr251 and the carbonyl group of maraviroc
(Fig. 6K) is formed. The phenyl group penetrates a channel leading to
ECL2. Alternatively the 1,3,4-triazole moiety could form a hydrogen
bond interaction with Tyr251, in which case the interaction with Ile198
is more likely of an indirect nature. The diﬂuoro-cycloalkyl and phenyl
moieties of maraviroc could interact with Trp86 (Fig. 6L). Silent
mutations were Leu33, Tyr37, Phe109, Phe112, Asn252 and Leu255.
Several binding modes for each compound could potentially ex-
plain the experimental results. However, the hydrophobic nature of
the binding sitemakes it difﬁcult to differentiate between the different
binding modes proposed here including proposed interaction models
from the literature. In order to reﬁne existing binding modes, ad-
ditional mutations with substitutions other than alanine, small
molecule SAR or mutant ﬁngerprint data on structurally closely
related compounds could be useful (Ballesteros and Palczewski, 2001).Discussion
Given the difﬁculties in obtaining crystals of membrane-bound
proteins, and hence GPCR crystal structures, the usual approach to
decipher the potential binding interactions is to determine the impact
of amino acid mutations on ligand binding efﬁcacy. These mutagen-
esis data can then be utilized to generate binding models by docking
small molecules into the binding site of a receptor homology model
based on a structural template.
It is well known and experimentally proven that GPCRs are able to
adopt a number of inactivated and activated conformations (Kenakin,
2004, 2005). With this caveat in mind the CCR5 homology model
utilized here is useful in identifying residues as potential interaction
sites for small molecules and developing binding models. Alternative
models have been suggested in the literature (Billick et al., 2004;
Castonguay et al., 2003; Dragic et al., 2000; Kondru et al., 2008; Maeda
et al., 2006; Nishikawa et al., 2005; Seibert et al., 2006; Stupple et al.,
2011; Tsamis et al., 2003).
Since suchmutagenesis data cannot be used to precisely deﬁne the
correct binding mode, all of these docking models can be used as
starting points for rational drug design. It has to be kept in mind that
this is an indirect approach for investigating the interactions of small
molecules with the receptor, and some mutations can indirectly
impact ligand binding. Secondly, silent mutations can be created if thefor clarity only the transmembrane region at the extracellular end is depicted.
237J. Labrecque et al. / Virology 413 (2011) 231–243functional response of the assay does not depend on a certain ligand–
receptor interaction.
In our study the mutations used have little or no effect on CCR5
expression and conformation as demonstrated by the lack of effect of
the mutations on baseline fusion compared with wild type CCR5. In
addition, for most of the CCR5 mutants a variance of fold change of
inhibition was observed for each of the six compounds. For example,
in the case of the E283A mutation the fold changes in Table 2
range from 5.5-fold (TAK-779) to 12,109-fold (vicriviroc). The W86AFig. 6. Potential binding modes of small molecule antagonists to CCR5; only amino acids are d
hydrogen atoms are omitted for clarity: A) binding of SCH-C; carbonyl group interacts with T
vicriviroc. E) binding of aplaviroc; interaction with K191; F) binding of aplaviroc; interactio
group interacts with T105, carbamate group with T284. J) Binding of 3bb; sulfonyl group int
interacts with Y251. L) Binding of maraviroc; the 1,3,4-triazole interacts with Y251. Atom comutation might represent an exception with a lower fold decrease of
83 and an upper fold change of 1367 (Table 2). Residues in this part of
CCR5 have been identiﬁed as important for signal transduction (Arias
et al., 2003; Govaerts et al., 2003). Therefore we conclude that most of
the mutations do not change the overall geometry of the CCR5
receptor and that the CCR5/gp120 fusion is not impacted by the
mutations.
The effects of silent mutations offer insights into different re-
quirements for efﬁcient allosteric inhibition for small moleculeepicted, which show> 10-fold change in inhibition of fusion upon alanine substitution;
105; B) binding of SCH-C; oxime group interacts with T105; C) and D) binding modes of
n with K26; G) and H) potential binding modes of TAK-779; I) binding of 3bb; sulfonyl
eracts with T284, carbamate group with T105. K) Binding of maraviroc; carbonyl group
loring: gray: carbon; red: oxygen; blue: nitrogen; yellow: sulfur and light green: ﬂuor.
}Fig. 6 (continued).
238 J. Labrecque et al. / Virology 413 (2011) 231–243antagonists in the particular assay used (vide infra). In order to
develop a comprehensivemechanistic picture it is therefore necessary
to consider all available experimental data including from the
literature.
In the assay validation the effects of CCR5 amino acid mutations on
small molecule inhibition in the fusion assay were compared with the
results obtained from 125I-RANTES competition binding and HIV
assays. The 125I-RANTES competition binding assay is membrane-
based and investigates the ability of small molecules to compete with
the natural ligand binding, while the fusion and HIV assays are
functional assays and representative of the therapeutic endpoint of
preventing HIV from entering the cell. The comparative data showsthat the fusion assay results for each compound were qualitatively in
agreement with the binding and HIV assay results as well as literature
data. Moreover, the results show that residues like Leu33, Tyr37, Trp86,
Tyr108 and Glu283 that have been shown to be critical for small
molecule binding by other techniques were also identiﬁed to be
critical with the fusion assay. The fusion assay has therefore been used
to investigate the binding of compounds to human CCR5 mutants in
more detail, utilizing a wider array of mutations with the ultimate
goal of deriving preferred binding modes based on these data.
A discussion of resistant mechanisms is beyond the scope of this
paper. For each compound the varying degree of fold changes upon
mutation could suggest different requirements for allosterism and
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to speculate that with the knowledge of the binding mode of the
different compounds, and the gp120 mutations contributing to virus
resistance, that one could hypothesize whether or not one CCR5
antagonist is cross-resistant to another based on the model of Tilton et
al. (2010). However Tilton et al. also indicate that there is no
straightforward correlation between in vitro resistance studies and
treatment failure in CCR5 antagonist regimens suggesting amultiplicity
of factors are responsible for treatment failure.
All binding modes presented here for different CCR5 antagonists
are characterized by an ionic interaction between a positively charged
nitrogen and Glu283, and this premise is supported by observations
reported in the literature (Billick et al., 2004; Dragic et al., 2000;
Castonguay et al., 2003; Kondru et al., 2008; Maeda et al., 2006;
Nishikawa et al., 2005; Seibert et al., 2006; Stupple et al., 2011; Tsamis
et al., 2003) and our own mutant data. Furthermore, the compounds
span the cross section of the binding site forming mainly hydrophobic
interactions with aromatic and aliphatic residues. Sincemaraviroc and
vicriviroc do not show any other potentially more discriminating
interactions, these compounds can be docked in several ways into the
binding site. Other compounds, like SCH-C, 3bb and TAK-779, form
additional hydrogen bond interactions with Thr284 and/or Tyr105
justifying more speciﬁc binding modes. Similarly, the structural
features of aplaviroc allow the formation of weaker ionic interactions
with residues in the extracellular region as indicated by the impact of
the K26A and K191A mutations on fusion inhibition and this
observation is supported by experimental data from the literature
(Maeda et al., 2006). An interesting conclusion from these results is
that all compounds interact with the receptor by assuming distinct
orientations with Glu283 as a center of inversion. However, the
hydrophobic nature of the two sub-pockets ﬂanking the polar center
enable different ligand binding modes which need to be taken into
account when interpreting mutation data.
In agreement with results presented here the small molecule
binding site of CCR5 based on mutant data in different assays (e.g.
125I-MIP-1α, 125I-RANTES, monoclonal antibodies, HIV-entry with
different strains and radiolabeled small molecules) is located
beneath the ECL2. However, a more detailed analysis of the data
reveals that the experimentally observed mutant fold changes are
different. This can be explained by different assay set ups and
requirements for allosterically inhibiting natural ligands, antibodies
or HIV strains (Blanpain et al., 2003; Dragic, 2001; Mansﬁeld et al.,
2009). As a consequence the derived binding modes can vary and
this is described in more detail for the following speciﬁc literature
studies.
An entry assay using HIV-1 JR-FL isolates was applied to study the
binding interactions of CCR5 with TAK-779, SCH-C and AD101, a
compound structurally closely related to vicriviroc (Seibert et al.,
2006). In support of our experimental observations the same residues
were identiﬁed as being crucial (e.g. Leu33, Tyr37, Trp86, Tyr108 and
Glu283). However, a more detailed comparison also reveals differ-
ences. Most notably, while Seibert et al. (2006) indicate only a small
change in inhibition for the compounds tested upon I198A mutation,
our experimental observations render SCH-C and vicriviroc sensitive
to this alanine substitution (Table 2). As a result Seibert et al. (2006)
suggest that Ile198 is not part of the ligand binding site for SCH-C,
AD101 and TAK-779. Instead an indirect interaction was postulated
allowing these compounds to bind deeper into the TM1, TM2, TM3
and TM7 region of the receptor. In contrast our proposed binding
modes, which take into account published data, suggest that the
compounds penetrate less deeply into the receptor, thus allowing a
direct interaction with Ile198.
Another study (Nishikawa et al., 2005) identiﬁed Asn252 and
Leu255 in TM5 as interaction sites for TAK-779. Despite not conﬁrming
these results with our fusion studies, our docking results with TAK-
779 did suggest that Asn252 and Leu255 could potentially function asinteraction sites. Different requirements for allosteric inhibition of
HIV-1 JR-FL and the antifusogenic assay used here could explain the
difference in experimental observations. Indeed, simple concentration
differences for the same assay have been used to explain the
difference in mutagenesis studies (Nishikawa et al., 2005).
A study on CCR2b (Berkhout et al., 2003) investigating the impact
of residue mutations on MCP-1 binding inhibition of TAK-779
suggests a similar binding mode to the ones presented in this paper.
Indeed, the sequence similarity of CCR2b and CCR5 is high in the
transmembrane region, especially in the TM1, TM2 and TM7 part. In
addition, the rather large hydrophobic biphenyl moiety could form
unselective interactions with residues in the remaining part of the
binding site and could account for this cross-reactivity.
Binding experiments with radiolabeled TAK-779, SCH-C and
aplaviroc using a panel of mutants identiﬁed residues Tyr37, Tyr108,
Lys191 and Glu283 as crucial interaction sites (Maeda et al., 2006) and
our docking studies place these compounds in the same region of the
CCR5 receptor. However, we placed more emphasis on ionic
interactions, for example, we consider the Glu283-protonated nitrogen
interaction as crucial in contrast to Maeda et al. (2006). Using this
interaction as a basis for manual docking, we determined that
aplaviroc is able to interact with Lys191 of ECL2. While our studies
did ﬁnd a small dependency of aplaviroc's inhibition on the K191A
mutation, the radiolabeling study described in Maeda et al. (2006)
determined that Lys191 is an important interaction site for aplaviroc.
The difference between the two studies could be explained with a
ternary system, in which gp120 interactions are changing the
receptor's conformation and possibly increasing the afﬁnity of
aplaviroc to CCR5 (Tagat et al., 2001). Thus, Lys191 could serve as a
potential interaction site for aplaviroc (Fig. 6E) but the importance of
this residue for compound binding could vary with the conformation
of CCR5 induced by different assays and different ligands. The results
of the K26A mutation (Table 2) also suggest a weak interaction of
Lys26 with aplaviroc (Fig. 6F). The suggested binding mode for SCH-C
and TAK-779 derived for the radiolabeled small molecule binding
study (Maeda et al., 2006) agree with our results shown in Fig. 6B and
H. In addition, our experimental results and docking studies suggest
an additional binding mode for each compound (Fig. 6A and G).
In a recent study the binding modes of ﬁve CCR5 antagonists
(Kondru et al., 2008) were determined by using a radiolabeled
RANTES bindingmutant assay but compared to our study less mutants
were investigated and the mutant fold increases differed substantial-
ly. For example, the impact of mutations such as L33A, Y37A, F79A,
T105A, and T284A, as well as the mutant SAR such as Y37A and Y37F
or Y215A and Y251F were not determined. Given the number of
mutants studied and the assay differences, this could account for the
variations of the mutant fold increases. For example, the W86A
mutation has a less dramatic impact in the ligand binding assay
compared to the fusion assay. Despite the fact that the binding modes
proposed by Kondru et al. (2008) span across the whole cross section
of the receptor utilizing Glu283 as an anchor point, only one speciﬁc
binding mode per compound was suggested. On the other hand, our
results, based on the availability of a larger set of mutations, suggest a
model encompassing two alternative binding modes per compound.
The binding of 2-aryl-4-(piperidine-1-yl)butanamines and 1,3,4-
trisubstituted pyrrolidines to human CCR5 have also been investigat-
ed (Castonguay et al., 2003). Based on the effects of amino acid
substitutions on the competition of these compounds against 125I-
MIP-1α binding, Tyr37, Tyr108, Trp86, Tyr251, and Glu283 have been
identiﬁed as important interaction sites. This data together with small
molecule SAR data was used to suggest a binding mode in which part
of the molecule interacts with residues in the ECL2. No further
mutations in the transmembrane region (e.g. I198A) or the extracel-
lular region were investigated. However, our studies identiﬁed Ile198
in TM-V as a potential binding site, whereas none of the ECL2
mutations impacted the fusion inhibition of 3bb. As a consequence,
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whole cross section of the small molecule antagonist binding site
(Fig. 6I and J).
Similar mutant approaches to understand small molecule binding
to chemokine receptors have been utilized in the case of CCR1 (de
Mendonca et al., 2005; Vaidehi et al., 2006), CCR2b (Berkhout, et al.,
2003;Mirzadegan et al., 2000), CXCR1 (Bertini, et al., 2004) and CXCR4
(Gerlach et al., 2001; Trent et al., 2003; Rosenkilde et al., 2004; Wong
et al., 2008). A discussion of the properties of chemokine receptors and
their small molecule antagonists can be found in Allen et al. (2007).
Nonetheless, it is worth mentioning that the putative small-molecule
inhibitor binding site of these chemokine receptors is similar to the
CCR5 small molecule antagonist site and is located in the extracellular
transmembrane region deﬁned by helices TM1, TM2, TM3, TM5, TM6,
and TM7, and beneath ECL2 (Fig. 1). Furthermore, compared to CCR5,
the second coreceptor important for HIV entry, CXCR4, consists of a
highly negatively charged small molecule binding pocket, as deter-
mined by mutant experiments using radiolabeled SDF-1α or HIV-1
env-mediated fusion. This is also reﬂected in the highly positively
charged character of CXCR4 small molecule antagonists.
Conclusions
In summary, different assays (natural ligand binding, HIV-1 and
an antifusogenic assay) and amino acid mutations as well as
information from the literature have been used to derive an
understanding of how small molecule antagonists interact with
CCR5. The interpretation of this data allows the development of a
mechanistic picture which is characterized by several alternative
bindingmodelswhich can be used as a starting point for rational drug
design.
This study probes the interaction of several structurally distinct
small molecule CCR5 antagonists at different stages of drug
development with a fusion assay. Based on an assay comparison this
fusion assay presents an alternative to studying ligand–receptor
interactions on amolecular level as close as possible to the therapeutic
endpoint, which is HIV infection. This assay is both convenient and has
none of the safety risks associated with other techniques (i.e. no
radioactivity and no infection risk) currently used for CCR5 mutagen-
esis. In addition the assay has a short turnaround time compared with
the HIV-1 infection assays, and is amenable to use in a high-
throughput mode. By using transient transfection, we have been
able to investigate an increased number of mutations thus allowing us
to more completely explore the inhibitor binding site. These results
enabled us to postulate two distinct binding modes for each com-
pound one of which was not described in the literature. The value of
these additional binding modes has been used to design novel CCR5
antagonists that will be published shortly.
Materials and methods
Cell lines
TheHEK293F human embryonic kidney cell linewas obtained from
the ATCC, Manassas, USA and the CHO-Tat-10 cell line was obtained
under license from the Gladstone Institute, San Francisco, CA, and the
HeLa-CD4-LTR-β-gal was obtained from the NIH AIDS Research and
Reference Reagent Program. HEK293F cells were maintained in
Dulbecco's modiﬁed Eagle's medium supplemented with 10% fetal
bovine serum (FBS), 1 mM sodium pyruvate, 1 mM non-essential
amino acids, and 4 mM L-glutamine. The CHO-Tat-10 cell line was
maintained in RPMI 1640 media, supplemented with 10% fetal bovine
serum, 2 mM glutamine, 1 mM sodium pyruvate, 1× non-essential
amino acids, 0.5 mg/ml geneticin, and 12 μg/ml puromycin. The HeLa-
CD4-LTR-β-gal was maintained in Dulbecco's modiﬁed Eagle's medi-
um supplemented with 10% FBS, 4 mM glutamine, 1 mM sodiumpyruvate, and 1× non-essential amino acids, 0.2 mg/ml geneticin and
0.1 mg/ml hygromycin. All cell culture media and supplements were
obtained from Hyclone Inc., Logan, Utah, with the exception of fetal
bovine serum, which was obtained from Invitrogen Inc., Carlsbad, CA,
and hygromycin, which was obtained from Calbiochem.
Human astroglioma U87 cells expressing human CD4 (U87.CD4)
[1] were a kind gift of Dr. Dan Littman (Skirball Institute of Bio-
molecular Medicine, New York University Medical Center, New York,
NY) and were cultured in Dulbecco's modiﬁed Eagle's medium (Gibco
BRL) containing 10% fetal bovine serum (FBS) (Hyclone, Perbio,
Erembodegem, Belgium), 0.01 M HEPES buffer (Gibco BRL), and
0.2 mg/ml geneticin (G-418 sulfate) (Gibco BRL). The cell cultures
were maintained at 37 °C in a humidiﬁed 5% CO2-controlled
atmosphere and subcultivations were done every 2 to 3 days by
digestion of the monolayers with trypsin/EDTA (Gibco BRL).
Site-directed mutagenesis of the CCR5 receptor
Human CCR5 cDNA was cloned into the expression vector
pcDNA3.1 (Invitrogen, Carlsbad, CA). Point mutations were intro-
duced into the CCR5 receptor using the Stratagene QuikChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA) according to the
manufacturer's instructions, and sub-cloned into the pcDNA3.1 TOPO
vector. Sequences of receptor constructs were conﬁrmed by DNA
sequence analysis (NAPS Unit, UBC, Vancouver, BC).
Expression of mutant receptors
Stable transfectants were isolated in order to prepare CCR5 mem-
branes for ligand binding assays. HEK293F cells were plated onto
15 cm culture dishes, 3×107 cells per dish and transfected with wild
type CCR5 or mutant constructs using Lipofectamine2000 (Invitrogen
Inc.) according to the manufacturer's instruction. Following trans-
fection the cells were diluted with medium supplemented with
800 μg/ml geneticin. Single colonies were selected and expanded,
maintaining the geneticin selection. Cell surface expression of the
receptors was conﬁrmed by ﬂow cytometry using the anti-CCR5
phycoerythrin-conjugated 2D7 monoclonal antibody (Pharmingen).
Transient transfectants were prepared for the CCR5 fusion assay.
The pcDNA3.1 vector containing wild type or mutant CCR5 was
ampliﬁed in E. coli DH5α competent cells. The plasmid DNA was
isolated using the Qiagen Endofree Plasmid Maxi Kit according to the
manufacturer's protocol (Qiagen, Mississauga, ON). Four days before a
fusion experiment, 2.2×106 HeLa-CD4-LTR-β-gal cells were plated in
a 6 cm culture dishes with 3 ml of growth medium without geneticin.
The cells were incubated overnight at 37 °C, 5%CO2. The following day
the cells were transfected with 8 μg of pcDNA3.1 construct using
Lipofectamine2000 (Invitrogen Inc.) according to the manufacturer's
instruction. The cells were split the following day into 10 cm culture
dishes containing medium without geneticin, incubated overnight
and the fusion assay was performed 48 h after transfection.
The pcDNA3.1 expression vectors encoding the different forms of
CCR5 were cotransfected with the pPUR selection vector encoding
puromycin resistance (CLONETECH Laboratories, Palo Alto, CA) into
U87.CD4 cells by the use of FuGENE 6 Transfection Reagent (Roche
Molecular Biochemicals, Mannheim, Germany) according to the
manufacturer's instructions. Puromycin selection (1 μg/ml) was
started after 24 h. We established a puromycin-resistant cell culture
after approximately 2 weeks. However, only 1–5% CCR5-positive cells
were established for each of the CCR5 variants (as determined by ﬂow
cytometry). CCR5-expressing cells were isolated from these cell cul-
tures as follows. Approximately 4×106 cells in 500 ml of PBS
containing 2% FBS were incubated with 20 μl of nonconjugated
mouse anti-human CCR5 antibody clone 2D7 (BD PharMingen, San
Diego, CA) for 30 min at room temperature. After two washing steps,
the cells were incubated with 2×106 sheep anti-mouse IgG
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with 2% FBS for 1 h at 4 °C under continuous gentle rotation.
Thereafter, the CCR5-positive cells (which had bound magnetic
beads at their surface) were isolated from the cell suspension by
magnetic separation and were thoroughly washed with PBS and
transferred to puromycin-containing growth medium.
125I-RANTES binding assay
The 125I-RANTES binding assay was performed with membranes
containing the CCR5 receptor prepared from HEK293F cells trans-
fected with either wild type or mutant CCR5. The transfected cells
were grown to conﬂuence, lifted with Versene, washed twice with
Dulbecco's–PBS and resuspended in cold buffer containing 5 mM Tris,
5 mM EGTA, 5 mM EDTA, 0.1 mM PMSF, pH7.4 (Buffer 1). The cells
were homogenized with a Polytron Homogonizer (2×10 second
bursts at a speed setting of 7). Additional Buffer 1 was added and the
suspension centrifuged at 1100 rpm for 6.5 min to remove cell debris.
The supernatant was aspirated and centrifuged at 45,000 g for 30 min.
The pellet was resuspended in 50 mM Tris, 5 mM MgCl2, pH7.4
(Buffer 2) followed by 2 washes. After the ﬁnal spin, the pellet was
resuspended in a minimal volume of Buffer 2 and remaining clumps
broken up with a Dounce Homogonizer. Protein content was
determined using the Bradford assay. The membrane was resus-
pended at a ﬁnal concentration of 1 mg/ml in Buffer 2 containing a
ﬁnal concentration of 250 mM sucrose. The membrane preparation
was ﬂash frozen in liquid nitrogen and stored at −80 °C.
For the binding assay 96-well Millipore Multiscreen plates with
GF-B membranes (Millipore Corp., Beford, MA) were pre-wet with
100 μl nanopure H2O, aspirated and blocked for 90 min at 4 °C with
75 μl 0.15% PolyEthyleneImine. The PEI was aspirated and the blocked
plates washed with 100 μl reaction buffer (50 mM HEPES, 5 mM
MgCl2, 1 mM CaCl2, 0.2% BSA, pH7.4). Immediately before use, the
CCR5 membranes were diluted in assay buffer to a concentration of
0.16–0.28 μg/μl in a ﬁnal volume of 50 μl. The 125I-RANTES (Perki-
nElmer Life Sciences, 2200 Ci/mmol) was diluted to a ﬁnal concen-
tration of 50 pM. 50 μl membrane was incubated with 25 μl 125I-
RANTES, and 50 μl buffer or compound over a concentration range of
1×10−5 to 6.4×10−10 M for 45 min at room temperature. The plates
were washed 3 times with ice-cold 50 mM HEPES, 0.5 M NaCl, pH7.4,
dried and counted on a Wallac 1450 Microbeta Jet liquid scintillation
counter. Ligand binding dose/response curves were analyzed and IC50
values calculated using PRISM 3.0 (GraphPAD).
CCR5 fusion assay
A cell–cell fusion assay was used to mimic the ﬁrst stage of the HIV
infection process. The principle of the assay is the fusion of one cell
line expressing the HIV-1 JRFL viral envelope protein and the Tat
transcription factor (CHO-Tat10) with a second cell line (HeLa-CD4-
LTR-β-gal) expressing CD4 and CCR5 and the LacZ gene under the
control of the HIV-1 LTR promoter.
Transfected HeLa-CD4-LTR-β-gal cells were washed with PBS and
lifted with 40 mM Tris pH7.4, 1 mM EDTA pH=8.0 and 150 mM NaCl
(TEN buffer). The cells were washed by centrifugation and resus-
pended in fusion assay medium (DMEM: RPMI 1640 1:1 supplemen-
ted with 10% FBS) and concentration adjusted to 0.4×106 cells/ml.
Similarly conﬂuent CHO-Tat cells were washed with PBS, lifted with
TEN buffer and resuspended to a concentration of 0.4×106 cells/ml in
assay medium. Stock solutions of all compounds were prepared in
DMSO and subsequently diluted into the fusion assay medium. Equal
volumes of HeLa and CHO-Tat cells were then mixed just prior to
plating, and 50 μl of the cell mixture added to the wells of a 96 well
plate. 50 μl of diluted compound was then added to the cells to give
a ﬁnal concentration range of either 1×10−5 to 6.4×10−10 M, or 1×
10−6 to 6.4×10−12 M. The plates were incubated for 20 h at 37 °C, 5%CO2, and then assayed for β-galactosidase activity using the Gal-
Screen homogenous chemiluminescent reporter gene assay (Applied
Biosystems). The plates were read on a Victor 2 plate reader. IC50
values were calculated using non-linear regression curve ﬁtting
(ExcelFit 3.0).
HIV-1 infection assay
The U87.CD4.CCR5 cell variants were seeded in 24-well plates at
5×104 cells/ml in medium. The HIV-1 laboratory strain BaL was
added at a ﬁnal concentration of 10,000 pg/ml for all cell lines
mentioned above. To examine the antiviral activity of the CCR5
antagonists the cells were seeded in 24-well plates already containing
compounds at varying concentrations. Then, virus was added after a
preincubation period of 10 min and the plates were maintained at
37 °C in a humidiﬁed CO2-controlled atmosphere. The cytopathic
effect (syncytium or giant cell formation) in the virus-infected cell
cultures was evaluated microscopically 5 days after infection. Then
the supernatant was collected and analyzed for virus content based on
the p24 core Ag ELISA (DuPont-Merck Pharmaceutical Co., Wilming-
ton, DE). The potency of the tested compounds to inhibit viral
replication was calculated using non-linear regression curve ﬁtting
(ExcelFit 3.0).
Compounds
The compounds depicted in Fig. 3 were synthesized at AnorMED
Inc. according to literature methods. Note: where available the




methanone; Mr=557.54) (Palani et al., 2002).
TAK-779 (dimethyl-(tetrahydro-pyran-4-yl)-{4-[(3-p-tolyl-8,9-
dihydro-7H-benzocycloheptene-6-carbonyl)-amino]-benzyl}-ammonium
chloride; Mr=531.14) (Shiraishi et al., 2000).
Aplaviroc (4-{4-[1-butyl-3-(cyclohexyl-hydroxy-methyl)-2,5-
dioxo-1,4,9-triaza-spiro[5.5]undec-9-ylmethyl]-phenoxy}-benzoic







3-phenyl-butyl]-piperidin-4-yl}-carbamic acid 4-nitro-benzyl ester;
Mr=634.80) (Finke et al., 2001).
Maraviroc (4,4-diﬂuoro-cyclohexanecarboxylic acid {(S)-3-[3-(3-
isopropyl-5-methyl-[1,2,4]triazol-4-yl)-8-aza-bicyclo[3.2.1]oct-8-yl]-
1-phenyl-propyl}-amide; Mr=513.68) (Price et al., 2005).
Molecular modeling
Modeller within Insight2000.1 (Accelrys, Inc., San Diego, USA) was
used to generate the CCR5 homology model. Bovine rhodopsin (PDB
ID: 1HZX.pdb) (Teller et al., 2001) served as a template. The alignment
follows general rules for GPCRs to allow no gaps in the helix regions as
well as to align residues conserved across most of the GPCR class A
family (Onuffer and Horuk, 2002). The extra- and intracellular loops
were included. Several models of CCR5 were generated and the model
with the lowest probability density function (PDF) value and energy
was used for further loop reﬁnements. The model with the lowest PDF
valuewas subjected to energyminimizations in order to remove steric
clashes of the side chains. During these reﬁnements the helical Cα
coordinates of the transmembrane region of CCR5 were kept ﬁxed in
order to keep the helix positions as closely as possible to the crystal
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the region of helix II close to the extracellular region had to be
adjusted. CCR5 has in this region a TXP motif compared to bovine
rhodopsin's GGF motif. In order to accommodate this change, the
procedure in Paterlini (2002) was used. The Ramachandran plot of the
ﬁnal homology model shows most of the residues in the allowed
region. The structures of all compounds (Fig. 1) were generated with
Insight2000.1 and subjected to energy minimization with CVFF in
Discover (Accelrys, Inc., San Diego, USA). The structures were
manually docked into the CCR5 receptor model based upon the
mutant data followed by geometry optimizations with CVFF in
Discover keeping backbone atoms of the transmembrane region of
the receptor ﬁxed. Later in the project MOE2005.06 (Chemical
Computing Group, Montreal Canada) was used to dock compounds
into the binding site of the CCR5 homology model. SVL code from the
SVL exchange website (http://svl.chemcomp.com/) was downloaded
and modiﬁed to randomly position compounds into the binding site.
The ligand–receptor complexes were geometry optimized with the
MMFF94x force ﬁeld available in MOE. Similarly, backbone atoms of
the transmembrane region of the receptor were kept rigid during
geometry optimizations. After inspecting the produced binding
modes and making manual modiﬁcations in order to take mutagen-
esis data into account further restricted geometry optimizations were
performed.
Fig. 3 depicts CCR5 small molecule antagonists, whose dependen-
cies on different CCR5 mutants were determined in different assays.
For all compounds protonation states at pH=7.0 were adjusted.
Therefore SCH-C, vicriviroc, 3bb, maraviroc and TAK-779 are
positively charged, while aplaviroc represents a zwitterion. While
for most of the compounds their representative names have been
used, no name could be found for the compound originating from
medicinal chemistry efforts of Merck. In the current studies this
compound has been named by their reference number from the
original article: 3bb.References
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